Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study

PURPOSE: To evaluate long-term, real-world treatment patterns and outcomes of ranibizumab 0.5 mg for neovascular age-related macular degeneration (nAMD) in a Belgian cohort. PATIENTS AND METHODS: This Belgian (BE) cohort of the 5-year global observational LUMINOUS study included 229 patients with nA...

Descripción completa

Detalles Bibliográficos
Autores principales: Leys, Anita M, Ramboer, Eva, Favreau, Mérédis, Denhaerynck, Kris, MacDonald, Karen, Abraham, Ivo, Brié, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277576/
https://www.ncbi.nlm.nih.gov/pubmed/32581505
http://dx.doi.org/10.2147/OPTH.S242547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277576/
https://www.ncbi.nlm.nih.gov/pubmed/32581505
http://dx.doi.org/10.2147/OPTH.S242547

Ejemplares similares